The threat posed by treatment-resistant pathogens is imminent and identified as one of the biggest health challenges of the 21st century. AID researchers address this urgent need through discoveries on new treatment options for AMR pathogens, optimisation of currently available treatment options, and responsible use of antimicrobials with a focus on human and One Health.
- Drug discovery, optimisation, and repurposing
- Drug administration and delivery
- Biologics discovery and development
- Clinical trials
- Multi- and cross-disciplinary collaborations for patient-focused outcomes
- One Health approaches to responsible use of antimicrobials and prevention of AMR development
Impact:
- Discovery of antimicrobials from unique natural products and synthetic scaffolds
- Lead characterisation, optimisation, and pre-/early clinical validation
- Novel drug combinations
- Host-directed interventions in chronic infections (e.g., compassionate use)
- Clinical trials on optimal antibiotic delivery for accelerated pathogen clearance (e.g., RESPOND)
- Clinical trials on drug combinations and new delivery modes in chronic infection (e.g., FORMAT)
- One Health approaches to preventing AMR development and spread in agriculture and health systems